Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc. on February 17, 2017, reporting events occurring on February 13, 2017, and February 16, 2017. The filing addresses significant changes in executive leadership under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and executive compensation terms rather than operational financial results.
Material Changes
- Departure of CFO: Michael Becker resigned as Chief Financial Officer on February 13, 2017, for personal reasons. The Company stated the departure is unrelated to operations, policies, or practices.
- Consultant Agreement: Mr. Becker entered into a consultant agreement expiring December 15, 2017, to provide financial, investor, digital media, and public relations services.
- Appointment of Interim CFO: On February 16, 2017, Sergio Traversa, the Company's Chief Executive Officer, was named Interim Chief Financial Officer.
Management Commentary, Risks, and Compensation
The filing details the amended and restated employment agreement for Sergio Traversa, effective August 5, 2015. Key terms include:
- Base Salary: $350,000 annually.
- Bonus: Target of 40% of base salary based on individual and corporate objectives.
- Equity: Eligible for grants under the 2014 Stock Option and Equity Incentive Plan.
- Termination Provisions:
- Death/Disability: Accrued salary and COBRA; estate receives 3 months' salary upon death.
- Termination without Cause/Good Reason: 24 months of compensation, 24 months of health benefits, and immediate vesting of equity awards.
- Change in Control: 30 months of compensation, 24 months of health benefits, and immediate vesting of equity awards.
- Non-Solicitation: 24-month restriction on soliciting employees or clients following employment cessation.
Investor Verification Checklist
- Verify the transition plan for financial reporting and investor relations following the CFO departure.
- Confirm the duration and scope of Michael Becker's consulting role to ensure no conflict of interest.
- Review the full text of Exhibit 10.1 (Employment Agreement) for specific definitions of "Cause" and "Good Reason."
- Assess the impact of the CEO assuming the CFO role on the Company's internal controls and financial oversight.